Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News NICE to assess wider impact of new drugs

NICE to assess wider impact of new drugs

28th March 2014

The National Institute for Health and Clinical Excellence (NICE) is to broaden its assessment of potential new drug treatments.

Responsible for deciding on the use of drugs administered by the UK's NHS, the regulator has said it will now look at the "wider societal impact" of therapies. This means the ability to enable patients to return to work earlier than traditional treatments could be considered alongside the clinical cost-effectiveness.

Pharmaceutical companies have complained NICE is unfair in its restriction of certain drugs, with the UK approving fewer new products than the rest of Europe and the US. 

The new proposals were unveiled in a consultation document yesterday (March 27th) and will be implemented in autumn if approved.

In an interview with Reuters, NICE chief executive Andrew Dillon said the new framework "has the potential for increasing the number of positive appraisals that NICE produces, but that is only going to happen if companies offer the very best price to the NHS."ADNFCR-8000103-ID-801707558-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.